HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 22.72
+0.42 (1.88%)
At close: Aug 22, 2025, 2:57 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2017 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2017 - 2018 |
Deoxyribonucleic Acid Encoded Compound Library Screening Service | 97.57M | Log In | Log In | Log In | Log In | Upgrade |
Deoxyribonucleic Acid Encoded Compound Library Screening Service Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Fragment-based Drug Design/Structure-based Drug Design Research & Development Services | 90.96M | Log In | Log In | Log In | Log In | Upgrade |
Deoxyribonucleic Acid Encoded Compound Library Customization Service | 84.69M | Log In | Log In | Log In | Log In | Upgrade |
Deoxyribonucleic Acid Encoded Compound Library Customization Service Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Chemical Synthesis Services | 52.00M | Log In | Log In | Log In | Log In | Upgrade |
Chemical Synthesis Services Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Custom Development | 19.48M | Log In | Log In | Log In | Log In | Upgrade |
Compound Structure Intellectual Property Transfer Fee | 10.21M | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research Equity Transfer | 1.89M | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research Equity Transfer Growth | -88.90% | Log In | Log In | Log In | Log In | Upgrade |
Other | 14.27M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Customized Service | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Customized Service Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Full-time Equivalent Service | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Full-time Equivalent Service Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Other | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services - Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Drug Research and Development Services | - | Log In | Log In | Log In | Log In | Upgrade |
Self Contained Deoxyribonucleic Acid Encoded Compound Library Compound Structure Information and Screening Method | - | Log In | Log In | Log In | Log In | Upgrade |
Intellectual Property Transfer Fee For Compound Structure | - | Log In | Log In | Log In | Log In | Upgrade |
Intellectual Property Transfer Fee For Compound Structure Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 14.27M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2017 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2017 - 2018 |
Other | 780.75K | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -70.11% | Log In | Log In | Log In | Log In | Upgrade |
United States | 249.87M | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 52.21% | Log In | Log In | Log In | Log In | Upgrade |
China | 62.75M | Log In | Log In | Log In | Log In | Upgrade |
China Growth | -8.40% | Log In | Log In | Log In | Log In | Upgrade |
Denmark | 18.80M | Log In | Log In | Log In | Log In | Upgrade |
Denmark Growth | -8.13% | Log In | Log In | Log In | Log In | Upgrade |
United Kingdom | 14.57M | Log In | Log In | Log In | Log In | Upgrade |
United Kingdom Growth | 33.50% | Log In | Log In | Log In | Log In | Upgrade |
Japan | 9.59M | Log In | Log In | Log In | Log In | Upgrade |
Japan Growth | 103.57% | Log In | Log In | Log In | Log In | Upgrade |
South Korea | 5.09M | Log In | Log In | Log In | Log In | Upgrade |
South Korea Growth | -31.03% | Log In | Log In | Log In | Log In | Upgrade |
France | 4.62M | Log In | Log In | Log In | Log In | Upgrade |
France Growth | -88.72% | Log In | Log In | Log In | Log In | Upgrade |
Other Countries | 3.76M | Log In | Log In | Log In | Log In | Upgrade |
Other Countries Growth | 1.29% | Log In | Log In | Log In | Log In | Upgrade |
Germany | 1.49M | Log In | Log In | Log In | Log In | Upgrade |
Germany Growth | -76.03% | Log In | Log In | Log In | Log In | Upgrade |
Other | 780.75K | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -70.11% | Log In | Log In | Log In | Log In | Upgrade |
Switzerland | - | Log In | Log In | Log In | Log In | Upgrade |